

Attorney Docket No.: 4401.214-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dyrberg et al.

Serial No.: 09/847,623

Group Art Unit: 1639

Filed: May 2, 2001

Examiner: B. Celsa

Confirmation No: 6709

For: Treatment of Type I Diabetes

RECEIVED  
CENTRAL FAX CENTER  
OCT 25 2004CERTIFICATE OF FACSIMILE TRANSMISSION  
703-872-9306Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. Petition and Fee for Extension of Time
2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of  
Examiner B. Celsa Confirmation No: 6709, fax number (703) 872-9306.

Respectfully submitted,

Date: October 25, 2004

  
Csaba Attila Szakolczai  
Novo Nordisk® Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

Attorney Docket No.: 4401.214-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Dyrberg et al.

Application No.: 09/847,623

Group Art Unit: 1639

Filed: May 2, 2001

Examiner: B. Celsa

For: Treatment of Type I Diabetes

**RESPONSE UNDER 37 C.F.R. § 1.116**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed April 28, 2004, in the above-identified application, kindly consider the following remarks.

Listing of Claims are set forth starting at Page 2 of this paper.

Remarks concerning these amendments are set forth beginning at Page 3 of this paper.